Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Vidaza in Advanced NSCLC
NCT02009436Phase 1Completed
- Sponsor
- Albert Einstein College of Medicine
- Start
- Feb 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in non-small cell lung cancer (NSCLC), sponsored by Albert Einstein College of Medicine. Primary endpoints: Maximum Tolerated Dose, Pulmonary Toxicity and 1 more. Started Feb 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02009436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009436.